Key Takeaways:
- JPMorgan resumes coverage on BeiGene with an "Overweight" rating.
- The bank sets a new price target of $415 for the company's US-listed shares.
- BeiGene stock jumped more than 10 percent in pre-market trading on the news.
Back
BeiGene stock soars over 10% on JPMorgan upgrade
BeiGene's US-listed shares surged more than 10 percent after JPMorgan resumed coverage of the biotechnology firm with an "Overweight" rating and a $415 price target.
The upgrade was announced in a research note from the bank on May 20, re-establishing its view on the global oncology company. An "Overweight" rating from JPMorgan suggests the firm expects the stock to outperform the average return of the stocks in the analyst's coverage universe over the next 6 to 12 months.
The new $415 price target represents a significant premium to the stock's prior closing price, triggering the strong positive reaction from investors in pre-market trading. The more than 10 percent jump reflects renewed confidence following the bank's endorsement.
The positive rating from a major financial institution like JPMorgan can significantly boost investor confidence, leading to increased buying pressure. The move may also draw positive attention to the broader biotech sector as investors look for opportunities in drug development and innovation.
This article is for informational purposes only and does not constitute investment advice.
